Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021:1342:113-142.
doi: 10.1007/978-3-030-79308-1_4.

Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?

Diego L Kaen  1 , Nicolas Minatta  2 , Alessandro Russo  3 , Umberto Malapelle  4 , Diego de Miguel-Pérez  5 , Christian Rolfo  6
Affiliations
Review

Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?

Diego L Kaen et al. Adv Exp Med Biol. 2021.

Abstract

Over the last few years, agents targeting immune checkpoints have shown potential to improve therapeutic outcomes in patients with lung cancer in multiple clinical settings. Inhibitors of PD-1/PD-L1 have been approved for the treatment of different types of lung cancer by the FDA either alone or in combination with chemotherapy or other immune checkpoint inhibitors, such as anti-CTLA-4 agents. The introduction of these agents in clinical practice has revolutionized the therapeutic approach to lung cancer, keeping the promises of long-term benefit in selected patient populations. The therapeutic indications of immunotherapy in lung cancer are rapidly growing, and multiple combinations entered clinical practice or are under active development. Furthermore, the quest for a reliable predictive biomarker is still ongoing to overcome the limits of currently approved tests for patients' selection. In this review, we summarized the current status and progress of anti-PD-1/PD-L1 agents in lung cancer treatment.

Keywords: CTLA-4; Immune checkpoint inhibitors; Immunotherapy; NSCLC; PD-1; PD-L1; SCLC; TMB; bTMB.

PubMed Disclaimer

References

    1. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer statistics, 2021. CA: a Cancer Journal for Clinicians, 71(1), 7–33. https://doi.org/10.3322/caac.21654 - DOI
    1. Thomas, A., & Giaccone, G. (2015). Why has active immunotherapy not worked in lung cancer? Annals of Oncology, 26(11), 2213–2220. https://doi.org/10.1093/annonc/mdv323 - DOI - PubMed - PMC
    1. Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer, 12(4), 252–264. https://doi.org/10.1038/nrc3239 - DOI - PubMed - PMC
    1. Wei, S. C., Duffy, C. R., & Allison, J. P. (2018). Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery, 8(9), 1069–1086. https://doi.org/10.1158/2159-8290.CD-18-0367 - DOI - PubMed
    1. Russo, A., McCusker, M. G., Scilla, K. A., Arensmeyer, K. E., Mehra, R., Adamo, V., & Rolfo, C. (2020). Immunotherapy in lung Cancer: From a minor god to the Olympus. Advances in Experimental Medicine and Biology, 1244, 69–92. https://doi.org/10.1007/978-3-030-41008-7_4 - DOI - PubMed

LinkOut - more resources